オプションチェーンは、Tharimmuneの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Tharimmuneの市場センチメントを評価します。.

Tharimmune (NASDAQ:THAR) 株価情報, オプションチェーン

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

BMO Capital analyst John Kim initiates coverage on Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announces Price Target of $71.

News

Price Target

Initiation

Analyst Ratings

TRNO

BMO Capital Initiates Coverage On Terreno Realty with Market Perform Rating, Announces Price Target of $71

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Monday.
U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 100 points during the session after President Donald Trump announced plans to pause tariffs against Mexico for one month. The index dipped as much as 665.6 points earlier during the session.
Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dipped 35% on Monday after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results. Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) posted better-than-expected first-quarter FY25 earnings results.
On the economic data front, U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November. The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December topping estimates of 49.8.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, information technology, and industrials stocks recording losses on Monday. However, utilities and consumer staples stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 123 points to 44,421.91 on Monday. The S&amp;P 500 fell 0.76% to 5,994.57, while the Nasdaq Composite fell 1.20% at 19,391.96 during Monday's session.
Investors are awaiting earnings results from Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 44.1, the index remained in the &#8220;Fear&#8221; zone on Monday, versus a prior reading of 40.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Markets

Trading Ideas

Dow Trims Losses After Trump Delays Mexico, Canada Tariffs: Greed Index Remains In 'Fear' Zone

Raymond James analyst John Freeman initiates coverage on Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announces Price Target of $135.

Raymond James Initiates Coverage On Expand Energy with Strong Buy Rating, Announces Price Target of $135

Popular dog-themed cryptocurrency Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) resumed its uptrend Monday, igniting a strong wave of optimism among bulls.
What happened: Dogecoin was up over 5% in the last 24 hours, recovering from the ‘Black Sunday' crash that eroded 28% of the value of the world's largest meme coin.
Dogecoin rose to an intraday high of $0.2924 in the evening hours before falling back to $0.26 due to profit-taking.
Well-known chartist Trader Tardigrade noted a bullish crossover of the Moving Average Convergence Divergence indicator, suggesting a potential shift in momentum toward an upward trend.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> MACD signals a Bullish Crossover on the 4-hour chart &#x1f525; <a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> is gaining upward momentum and could reverse into BULL RUN again &#x1f680; <a href="https://t.co/msUSKQTDUA">pic.twitter.com/msUSKQTDUA</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1886603784530616711?ref_src=twsrc%5Etfw">February 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another widely followed analyst, Kevin, stated that Dogecoin completed its "second major correction" of the bull cycle, a move "very similar" to the last cycle.
Kevin, who has previously linked Dogecoin's trajectory with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) moves, reaffirmed the opinion.&nbsp;
"If all goes well with BTC, then Doge should begin its next leg soon."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In my opinion <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> just completed its second major correction of its bull cycle. Very similar to last cycle and the drops in terms of percentage were very similar. If all goes well with <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> then <a href="https://twitter.com/hashtag/Doge?src=hash&amp;ref_src=twsrc%5Etfw">#Doge</a> should begin it&#39;s next leg soon. <a href="https://t.co/8eL3LeTawl">pic.twitter.com/8eL3LeTawl</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1886567742242709510?ref_src=twsrc%5Etfw">February 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/02/43454192/microstrategys-convertible-bonds-a-better-choice-than-spot-bitcoin-for-inclusion-in-sovereign-wealth-fund-says-analyst">Trump-Announced Wealth Fund Should Choose MicroStrategy Bonds Over Bitcoin, Analyst Says</a>
Why It Matters: The rally caused a spike in speculative interest for Dogecoin. Open Interest, or the notional value locked in unsettled Dogecoin future contracts, rose by 1.85% on Binance, <a href="https://www.coinglass.com/LongShortRatio">according </a>to Coinglass.
More than 79% of Binance traders were levered long on the meme coin, suggesting that the rally could be sustained in the short term.
Furthermore, the Commodity Channel Index, which measures the difference between the current price and the historical average price, fell below -150, <a href="https://in.tradingview.com/symbols/DOGEUSD/technicals/">according </a>to Trading View, signaling an oversold level and a potential "Buy."
Price Action: At the time of writing, Dogecoin was exchanging hands at $0.2616, up 5.14% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43455529/el-salvador-buys-the-dipnayib-bukele-led-nation-purchases-bitcoin-worth-over-a-million-after-market-crash">El Salvador Goes Bigger on Bitcoin: Daily Purchase Jumps 10x Amid Market Slump</a></li>
</ul>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

Dogecoin Regains Momentum After 'Black Sunday' Rout—Here's What Indicators Signal About The Memecoin's Next Moves

Piper Sandler analyst David Amsellem downgrades Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowers the price target from $66 to $36.

Downgrades

AMPH

Piper Sandler Downgrades Amphastar Pharma to Neutral, Lowers Price Target to $36

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) will release its fourth-quarter financial results, before the opening bell, on <a href="https://www.benzinga.com/quote/PFE/earnings">Tuesday, Feb. 4, 2025</a>.
Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in the year-ago period. Pfizer projects quarterly revenue of $17.26 billion, compared to $14.25 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, Pfizer revealed topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation.
Pfizer shares fell 1.2% to close at $26.20 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Guggenheim analyst Vamil Divan maintained a Buy rating and cut the price target from $35 to $33 on Dec. 11, 2024. This analyst has an accuracy rate of 76%.</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $29 on Dec. 10, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Barclays analyst Carter Gould maintained an Equal-Weight rating and raised the price target from $30 to $32 on July 31, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31, 2024. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying PFE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04041415/image-2-2-1024x593.png" alt="" class="wp-image-764340" style="width:497px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04041415/image-2-2-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04041415/image-2-2-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04041415/image-2-2-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04041415/image-2-2.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Piper Sandler analyst Michael Lavery upgrades Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) from Underweight to Neutral and maintains the price target from $58 to $58.

Upgrades

Piper Sandler Upgrades Tyson Foods to Neutral, Maintains Price Target to $58

Baird analyst Joel Beatty initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Outperform rating and announces Price Target of $28.

CPRX

Baird Initiates Coverage On Catalyst Pharmaceuticals with Outperform Rating, Announces Price Target of $28

TMUS

T-Mobile Plans Public Offering Of Euro-Denominated Senior Notes, Proceeds May Fund Buybacks, Dividends, And Debt Refinancing

Series of Appointments to Enhance Quant Capabilities and Accelerate Innovation
Northern Trust Asset Management (NTAM), a leading global investment management firm with US$1.3 trillion in assets under management as of December 31, 2024, announced a major expansion of its global quantitative investment strategies team.

NTRS

Northern Trust Asset Management Expands Quantitative Investment Team To Drive Innovation And AI-Driven Strategies

AT&amp;T extends voice core relationship with Nokia to drive new services, faster deployment times, and operational efficiencies
<ul>
<li>Multi-year expansion deal will support AT&amp;T in delivering on its vision of securely providing customer-focused networks and automation that drive new services, faster deployment times, and operational efficiencies.</li>
<li>Deal includes Nokia 5G IMS Voice Core and Nokia Digital Operations software.</li>
<li>AT&amp;T will utilize Nokia's voice core applications through the Nokia Cloud Platform to streamline network activities, enhance automation, and minimize manual intervention.</li>
</ul>

AT&T And Nokia Extend Partnership To Advance Cloud-Native Voice Core And Streamline Network Operations

CHKP

Check Point Enhances Infinity Platform With AI-Powered Innovations For Stronger, Smarter Cybersecurity

Fiscal 25 outlook Organic net sales growth In the second half of fiscal 25, before the impact of the tariffs, we would have expected to build on the momentum seen in the first half and would have expected to deliver a sequential improvement in organic net sales growth compared with the first half of fiscal 25. The confirmation at the weekend of the implementation of tariffs in the US could however impact this building momentum. We still expect to continue to deliver strong market share performance. Organic operating profit growth Before taking into consideration the potential impact of tariffs we had expected a slight decline in organic operating profit in the second half of fiscal 25 compared with the prior year, broadly in line with the decline in the first half, reflecting higher staff costs (given lower incentive comparatives in the same period last year), and continued strategic investments including in digital and US route-to-market. Clearly the implementation of tariffs could further impact this and when we can more accurately assess the impact we will update as appropriate.

Guidance

Diageo Anticipates Continued Strong Market Share In 2025, But Tariff Impact Remains A Key Watchpoint

Diageo H1 EPS $0.98 Down From $1.08 YoY, Sales $10.90B Down From $10.962B YoY

Group total revenue: Increased by 5.0% to €9.8 billion in Q3 with good organic service revenue growth partially offset by adverse foreign exchange movements.&nbsp;
− Group service revenue: Grew by 5.6% in Q3 to €7.9 billion and on an organic basis increased 5.2% (Q2: 4.2%), driven by broadbased growth, excluding Germany. The acceleration in quarterly trends was driven by the UK and Africa.
− Group Adjusted EBITDAaL: Increased by 2.2% on an organic basis to €2.8 billion, as service revenue growth in most markets and lower energy costs in Europe more than offset the impact of the TV law change in Germany. The Adjusted EBITDAaL margin of 28.8% was 0.5 percentage points lower year-on-year on an organic basis. On a year-to-date basis, Adjusted EBITDAaL increased by 3.2% on an organic basis to €8.2 billion. Operating profit decreased by 18.4% to €1.0 billion&nbsp;
− Share buybacks: Third €0.5 billion tranche completed 22 January 2025, with 1.8 billion shares repurchased for €1.5 billion since May 2024. Final €0.5 billion tranche from the initial €2 billion buyback programme commencing today.&nbsp;
− Group FY25 guidance reiterated: On track to deliver Group Adjusted EBITDAaL of c.€11 billion and Group Adjusted free cash flow of at least €2.4 billion. − UK merger: In December 2024, the UK's Competition and Markets Authority approved the combination of Vodafone and Three in the UK. We expect the merger to formally complete in the next few months.&nbsp;
− Vodafone Italy disposal: The sale of Vodafone Italy to Swisscom AG for €8 billion in cash completed on 31 December 2024. Proceeds have been used to reduce ne

Vodafone Group Q3 2025 Trading Update: Revenue €9.81B (+5% YoY) And Operating Profit €1.022B (-18.4% YoY); Reiterates FY25 Guidance

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) customers can now avail $7,500 federal EV tax credit on Cybertruck purchases provided they are eligible for it.
What Happened: The 2025 all-wheel drive variant of the Cybertruck is eligible for the tax credit, Tesla announced in a post on social media platform X. If the purchase price of the vehicle does not exceed $80,000 and the customer meets the gross income limitations for availing the tax credit, they can take ownership of the truck for $72,490.
The all-wheel drive version of the Cybertruck starts at $79,990 without tax credit. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">You want it, you got it Cybertruck now qualifies for $7500 federal tax credit <a href="https://t.co/k62vTYl2Tz">pic.twitter.com/k62vTYl2Tz</a>
&mdash; Cybertruck (@cybertruck) <a href="https://twitter.com/cybertruck/status/1886598710508859871?ref_src=twsrc%5Etfw">February 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The more expensive Cyberbeast variant of the truck starts at $99,990 and exceeds the price bar to be eligible for the tax credit. 
As per the U.S. government&#8217;s fueleconomy.gov&nbsp;website, the single-motor variant of the Cybertruck is also eligible for the tax credit but the company is yet to start the production of the variant. The <a href="https://www.benzinga.com/25/01/42759653/cybertruck-all-wheel-drive-now-eligible-for-7500-ev-tax-credit">rear-wheel drive single-motor variant</a> will start at $53,490 after the tax credit once delivery starts.
Why It Matters:&nbsp;Currently, all variants of the Model Y and Model 3 in addition to the Model X all-wheel drive variant sold in the U.S. are also eligible for $7,500&nbsp;electric vehicle consumer tax credits.
However, the very existence of the electric vehicle consumer tax credits is currently in question. In November, Reuters reported that President-elect&nbsp;Donald Trump's&nbsp;transition team is planning to kill the $7,500 consumer tax credit for electric vehicle purchases as part of broader tax-reform legislation. Tesla representatives reportedly supported the proposal to end the subsidy.
&#8220;In my view, we should end all government subsidies, including those for EVs, oil and gas,&#8221; Tesla CEO&nbsp;Elon Musk&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42005034/elon-musk-backs-calls-for-end-to-ev-subsidies-but-former-tesla-exec-warns-of-massive-drop-in-manufacturing-investments-if-trump-follows-through" target="_blank" rel="noreferrer noopener">wrote on X</a>&nbsp;following the report. &nbsp;
During Tesla's second-quarter earnings in late July, Musk alleged that the impact of the elimination of subsidies&nbsp;<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noreferrer noopener">would only be slight for Tesla</a>&nbsp;but devastating for its competitors. The elimination of EV subsidies would probably help Tesla in the long term, he added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43427393/tesla-rival-byd-marks-475-growth-in-january-passenger-vehicle-sales-driven-by-popularity-of-plug-in-hybrid-evs" target="_blank" rel="noreferrer noopener">Tesla Rival BYD Marks 47.5% Growth In January Passenger Vehicle Sales Driven By Popularity Of Plug-In Hybrid EVs</a></li>
</ul>
Photo courtesy: Tesla

Tech

TSLA

Tesla's Cybertruck Just Got More Affordable Thanks To $7,500 Tax Credit

El Salvador cashed in on the market slump Monday to add 11 Bitcoins (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), worth over $1 million, to its strategic reserve.
What happened: The Central American nation increased its daily purchases to 11, which is 10 more than the one Bitcoin per day policy, according to its treasury holdings tracker.
The latest grab boosted El Salvador's Bitcoin stockpile to 6,067.18, worth over $602 million at prevailing prices, with an unrealized profit of $321.26 million.
The Nayib Bukele-led nation was also the sixth biggest government holder of Bitcoin, <a href="https://bitcointreasuries.net/">according </a>to bitcointreasuries.net.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440; <a href="https://t.co/43pCyvNILP">pic.twitter.com/43pCyvNILP</a>
&mdash; Nayib Bukele (@nayibbukele) <a href="https://twitter.com/nayibbukele/status/1886567258400395678?ref_src=twsrc%5Etfw">February 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/02/43425216/elon-musk-supports-putting-treasury-department-operations-on-blockchain-to-fix-irregularities">Elon Musk Says Treasury Officials &#8216;Breaking The Law Every Hour&#8217; By Approving Fraudulent Payments — DOGE Lead Wants A Blockchain Fix</a>
Why It Matters: El Salvador became the first country to adopt Bitcoin as its legal tender in 2021,&nbsp; and it has <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41084132/nayib-bukeles-el-salvador-is-mainstreaming-bitcoin-by-putting-the-price-where-everyone-can">since pursued an ambitious strategy</a> to integrate the digital asset into the various aspects of its citizens' lives.
However, despite these efforts, the adoption of Bitcoin as a legal tender in the country <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40644084/el-salvador-president-nayib-bukele-says-bitcoin-uptake-hasnt-been-a-resounding-success-we-">hasn't seen the expected widespread uptake</a>.
Last week, the government <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43336076/el-salvador-changes-bitcoin-law-but-legal-tender-status-remains">scaled back its Bitcoin push</a>, making its acceptance voluntary rather than mandatory, to satisfy conditions set by the International Monetary Fund in return for a $1.4 billion loan agreement.
Price Action: At the time of writing, Bitcoin was exchanging hands at $99,538.22, up 5.51% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43423466/how-does-pete-hegseth-feel-about-bitcoin-his-financial-filings-reveal-the-answer">How Does Pete Hegseth Feel About Bitcoin? His Financial Filings Reveal The Answer</a></li>
</ul>
Photo courtesy: Shutterstock

Global

El Salvador Goes Bigger on Bitcoin: Daily Purchase Jumps 10x Amid Market Slump

ALGT

AMCR

AMGN

APAM

ARMK

ATEN

ATKR

AUDC

AVNW

AXTA

AZEK

AZPN

BALL

BERY

COLM

CRUS

CVRX

EGHT

ENPH

ENVA

FICO

FLNG

FOXA

GBDC

GOOG

GOOGL

HLNE

HUBB

ICHR

IESC

INGR

INMD

INNV

INTA

JKHY

JNPR

KLIC

KTCC

LANC

LARK

LUMN

MDLZ

MLAB

MPLX

MRCY

MSGS

MTCH

MUFG

OCSL

OSCR

PINC

PYPL

RACE

Earnings Scheduled For February 4, 2025

Mitsubishi UFJ Financial Group Nine Months 2024 NII ¥2.174T Up From ¥1.799T YoY; EPS ¥149.42 Up From ¥107.78 YoY

Shares of Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) fell nearly 4% on Robinhood overnight after the Chinese Ministry of Commerce added the company, along with Calvin Klein owner PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) to the unreliable entities list amid the ongoing trade war with the U.S..
What Happened: China claimed <a href="https://news.futunn.com/flash/18389865/department-of-commerce-add-the-us-pvh-group-and-immena?level=2&amp;data_ticket=1738646473129916">in</a> its press release that these two companies have disrupted normal market transactions and tried to harm the legitimate rights and interests of Chinese enterprises.
The specific measures to be taken against the companies have not yet been disclosed. However, they are expected to be in line with the &#8220;Regulations on the List of Unreliable Entities,&#8221; which allow for restrictions on trade, investment, and other business activities.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43454291/winner-winner-chicken-dinner-tyson-foods-q1-beat-showcases-improved-execution-in-poultry-says-ceo">Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases &#8216;Improved Execution&#8217; In Poultry, Says CEO</a>
Why It Matters: China&#8217;s State Administration for Market Regulation also announced on Tuesday that it will be investigating Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google for alleged anti-monopoly practices. This comes shortly after China imposed new tariffs on select U.S. goods, including coal, LNG, crude oil, farm equipment, and vehicles.
On Monday, President Donald Trump postponed his threat of imposing 25% tariffs on Mexico and Canada at the last minute, agreeing to a 30-day delay in exchange for concessions regarding border and crime enforcement with the two neighboring countries. However, there was no similar pause on the 10% tariffs imposed on China.
Illumina fell 3.89% on Robinhood overnight, whereas PVH had ended over 7% lower on Monday. The exchange-traded fund tracking the S&amp;P 500 index, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) had ended 0.67% lower to close at $597.77 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43427091/as-trump-imposes-tariffs-on-americas-3-largest-trading-partners-this-macro-strategist-calls-the-policy-a-tool-to-transition-us-to-a-more-sustainable-future-amid-grotesque-money-printing" target="_blank" rel="noreferrer noopener">As Trump Imposes Tariffs On America's 3 Largest Trading Partners, This Macro Strategist Calls The Policy A ‘Tool To Transition' US To A More Sustainable Future Amid ‘Grotesque' Money Printing</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Politics

Events

Economics

ILMN

Illumina Stock Tumbles Nearly 5% Overnight On Robinhood As China Adds ILMN, Calvin Klein Owner PVH To 'Unreliable Entities List' Amid Trade War With US

Tharimmune ( ($THAR) ) has provided an announcement. Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral versi...

Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( ($THAR) ) has shared an announcement. Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase ...

Tharimmune Announces Intent to Acquire Intract Pharma

Tharimmune (THAR) presented new TH104 Phase 1 data at the American College of Gastroenterology 2024 Annual Scientific Meeting, underway in Philadel...

Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in ...

Tharimmune presents clinical data on TH104 for chronic pruritus

Rodman & Renshaw analyst Elemer Piros initiated coverage of Tharimmune (THAR) with a Buy rating and $17 price target Published first on TheFly – th...

Tharimmune initiated with a Buy at Rodman & Renshaw

Tharimmune announces $2.02M private placement; shares up

Tharimmune (THAR) announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus associated...

Tharimmune announces Phase 2 study plan for TH104

Throughout 2024 Tharimmune (THAR) achieved significant milestones across three key areas. These accomplishments reflect progress in advancing innov...

Tharimmune provides business update, corporate highlights

16:19 EST Tharimmune (THAR) files to sell 1.44M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, m...

Tharimmune files to sell 1.44M shares of common stock for holders

Tharimmune files to sell 1.44 million shares of common stock by selling shareholders

THAR

Biotech

Press Releases

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Legal

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Cover – see more stocks inside…

New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback"

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Offerings

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Comments

Tharimmune

Tharimmune (THAR) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル